206 related articles for article (PubMed ID: 38710296)
41. Addressing Cancer Chemotherapeutic Toxicity, Resistance, and Heterogeneity: Novel Theranostic Use of DNA-Encoded Small Molecule Libraries.
Kolodny G; Li X; Balk S
Bioessays; 2018 Oct; 40(10):e1800057. PubMed ID: 30101540
[TBL] [Abstract][Full Text] [Related]
42. Nuclear medicine theranostics comes of age.
Herrmann K; Kraus BJ; Hadaschik B; Kunikowska J; van Poppel H; N'Dow J; Sartor O; Oyen WJG
Lancet Oncol; 2021 Nov; 22(11):1497-1498. PubMed ID: 34735807
[No Abstract] [Full Text] [Related]
43. Theranostic in Nuclear Medicine - The paradigm of NET.
Giammarile F
Hell J Nucl Med; 2023; 26 Suppl():42-43. PubMed ID: 37658562
[TBL] [Abstract][Full Text] [Related]
44. Advanced iron oxide nanotheranostics for multimodal and precision treatment of pancreatic ductal adenocarcinoma.
Zhu L; Mao H; Yang L
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2022 Jul; 14(4):e1793. PubMed ID: 35396932
[TBL] [Abstract][Full Text] [Related]
45. Copper radiopharmaceuticals for theranostic applications.
Ahmedova A; Todorov B; Burdzhiev N; Goze C
Eur J Med Chem; 2018 Sep; 157():1406-1425. PubMed ID: 30282317
[TBL] [Abstract][Full Text] [Related]
46. Recent advances in the development of nanoparticles for multimodality imaging and therapy of cancer.
Liu M; Anderson RC; Lan X; Conti PS; Chen K
Med Res Rev; 2020 May; 40(3):909-930. PubMed ID: 31650619
[TBL] [Abstract][Full Text] [Related]
47. Changing the Goal Posts: Prostate-specific Membrane Antigen Targeted Theranostics in Prostate Cancer.
Emmett L
Semin Oncol Nurs; 2020 Aug; 36(4):151052. PubMed ID: 32674976
[TBL] [Abstract][Full Text] [Related]
48. Radiolabeled inorganic nanoparticles for positron emission tomography imaging of cancer: an overview.
Chakravarty R; Goel S; Dash A; Cai W
Q J Nucl Med Mol Imaging; 2017 Jun; 61(2):181-204. PubMed ID: 28124549
[TBL] [Abstract][Full Text] [Related]
49. The emerging role of copper-64 radiopharmaceuticals as cancer theranostics.
Boschi A; Martini P; Janevik-Ivanovska E; Duatti A
Drug Discov Today; 2018 Aug; 23(8):1489-1501. PubMed ID: 29635027
[TBL] [Abstract][Full Text] [Related]
50. Advances in Molecular Imaging of Locally Delivered Targeted Therapeutics for Central Nervous System Tumors.
Tosi U; Marnell CS; Chang R; Cho WC; Ting R; Maachani UB; Souweidane MM
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28208698
[TBL] [Abstract][Full Text] [Related]
51. New Frontiers in Diagnosis and Therapy of Circulating Tumor Markers in Cerebrospinal Fluid In Vitro and In Vivo.
Sindeeva OA; Verkhovskii RA; Sarimollaoglu M; Afanaseva GA; Fedonnikov AS; Osintsev EY; Kurochkina EN; Gorin DA; Deyev SM; Zharov VP; Galanzha EI
Cells; 2019 Oct; 8(10):. PubMed ID: 31581745
[TBL] [Abstract][Full Text] [Related]
52. Nanoparticle Diagnostics and Theranostics in the Clinic.
Pallares RM; Mottaghy FM; Schulz V; Kiessling F; Lammers T
J Nucl Med; 2022 Dec; 63(12):1802-1808. PubMed ID: 36302654
[TBL] [Abstract][Full Text] [Related]
53. Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments.
Farolfi A; Fendler W; Iravani A; Haberkorn U; Hicks R; Herrmann K; Walz J; Fanti S
Eur Urol Oncol; 2019 Mar; 2(2):152-162. PubMed ID: 31017091
[TBL] [Abstract][Full Text] [Related]
54. Novel theranostic agents for next-generation personalized medicine: small molecules, nanoparticles, and engineered mammalian cells.
Kojima R; Aubel D; Fussenegger M
Curr Opin Chem Biol; 2015 Oct; 28():29-38. PubMed ID: 26056952
[TBL] [Abstract][Full Text] [Related]
55. Neuroendocrine Tumor Theranostics: An Update and Emerging Applications in Clinical Practice.
Sheikhbahaei S; Sadaghiani MS; Rowe SP; Solnes LB
AJR Am J Roentgenol; 2021 Aug; 217(2):495-506. PubMed ID: 34076455
[No Abstract] [Full Text] [Related]
56. GRPr Theranostics: Current Status of Imaging and Therapy using GRPr Targeting Radiopharmaceuticals.
Kurth J; Potratz M; Heuschkel M; Krause BJ; Schwarzenböck SM
Nuklearmedizin; 2022 Jun; 61(3):247-261. PubMed ID: 35668669
[TBL] [Abstract][Full Text] [Related]
57. Magnetic Nanoparticles in Cancer Theranostics.
Gobbo OL; Sjaastad K; Radomski MW; Volkov Y; Prina-Mello A
Theranostics; 2015; 5(11):1249-63. PubMed ID: 26379790
[TBL] [Abstract][Full Text] [Related]
58. Molecular theranostics: a primer for the imaging professional.
Lee DY; Li KC
AJR Am J Roentgenol; 2011 Aug; 197(2):318-24. PubMed ID: 21785076
[TBL] [Abstract][Full Text] [Related]
59. Molecular image-guided theranostic and personalized medicine 2014.
Zhang H; Tian M; Carrio I; Civelek AC; Fujibayashi Y
Biomed Res Int; 2015; 2015():258612. PubMed ID: 25883947
[No Abstract] [Full Text] [Related]
60. Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent.
Chatalic KL; Heskamp S; Konijnenberg M; Molkenboer-Kuenen JD; Franssen GM; Clahsen-van Groningen MC; Schottelius M; Wester HJ; van Weerden WM; Boerman OC; de Jong M
Theranostics; 2016; 6(6):849-61. PubMed ID: 27162555
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
